I��e seen Carl Icahn�� name in print nearly daily so I�� highly confident I can spell his surname with ease. The ��ighly confident��phraseology was Drexel Burnham speak, denoting its capacity to raise billions in capital for assorted greenmailers, LBO practitioners and takeover honchos who operated in the mid-seventies and eighties.
Carl graduated from this class of operators with distinction. It included Messrs. Riklis, Perelman, Ted Turner, Rupert Murdoch, Nelson Peltz, Leon Black and at least a dozen more anointed by Mike Milken who came through with deal financing.
I respect Icahn�� achievement. Over the years, Carl�� made more right decisions than clunkers. His net worth is unlikely to sink below $10 billion even in a bear market because he knows how to press sell buttons on major positions rather than marry them for life, Warren Buffett�� modus operandi.
Unlike Icahn, I never cottoned to Netflix, and actually sold Apple around $450. He owns Transocean and successfully browbeat management to increase its payout to shareholders. I�� in Halliburton, but just a silent investor.
5 Best Warren Buffett Stocks For 2014: Myriad Genetics Inc (MYGN.O)
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).
As of June 30, 2012, the Company h ad launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.
Molecular Diagnostic Tests
The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recu rrence and measure a patient's exposure to drug therapy to! e! nsure optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.
The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.
The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.
< p>Companion Diagnostic Services and Other RevenueThe Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeu tic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.
5 Best Warren Buffett Stocks For 2014: ZST Digital Networks Inc.(ZSTN)
ZST Digital Networks, Inc. engages in supplying digital and optical network equipment and providing installation services to cable system operators in China, as well as in providing GPS location and tracking services to local logistics and transportation companies in China. It offers a line of IPTV devices that are used to provide bundled cable television, Internet, and telephone services to residential and commercial customers. The company has assisted in the installation and construction of approximately 400 local cable networks in approximately 90 municipal districts, counties, townships, and enterprises. ZST Digital Networks has also launched a commercial line of vehicle tracking devices utilizing its GPS tracking technologies and support services for transport-related enterprises to track, monitor, and optimize their businesses. The company was founded in 1996 and is based in Zhengzhou City, the People?s Republic of China.
10 Best Small Cap Stocks To Invest In 2014: Rochester Medical Corporation(ROCM)
Rochester Medical Corporation engages in the development, manufacture, and marketing of PVC-free and latex-free urinary continence and urine drainage care products for the home and acute care markets. Its home care products include a line of silicone and latex male external catheters for managing male urinary incontinence; intermittent catheters for managing both male and female urinary retention, including Magic 3 line of silicone intermittent catheters; and the FemSoft Insert, a soft, liquid-filled, urethral insert for managing stress urinary incontinence in adult females. The company manufactures male external catheters in six models, including UltraFlex, Pop-On, Wide Band, Natural, Clear Advantage, and Transfix catheters; and intermittent catheters in four versions that include standard, antibacterial, hydrophilic, and antibacterial personal catheters. Its acute care products include a line of standard Foley catheters and Strata brand of Foley catheters; and Strata-NF Catheter, an antibacterial Foley catheter that reduces the incidence of hospital acquired urinary tract infection. The company?s primary customers include distributors, extended care facilities, and individual hospitals and healthcare institutions. It markets its products under the Rochester Medical brand name through a direct sales force in the United States, the United Kingdom, and the Netherlands, as well as through independent distributors in other international markets. The company also supplies its products to various medical product companies for sale under private label brands owned by these companies. Rochester Medical Corporation was founded in 1988 and is headquartered in Stewartville, Minnesota.
Advisors' Opinion:- [By Ben Levisohn]
Back in February, my colleague David Englander noted that a potential buyout was one reason to buy shares of Rochester Medical (ROCM). Today, Rochester agreed to be purchased by CR Bard (BCR) for $262 million.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Rochester Medical (Nasdaq: ROCM ) , whose recent revenue and earnings are plotted below. - [By Monica Wolfe]
Gabelli then made two separate buys into Rochester Medical (ROCM). On Sept. 4, the guru upped his stake by over 30% and on Sept. 5, Gabelli added an additional 10.21%. The guru purchased a total of 227,600 shares at an average price of $19.90 per share. Gabelli now holds on to a total of 750,110 shares, representing about 6.12% of the company�� shares outstanding.
5 Best Warren Buffett Stocks For 2014: Platinum Group Metals Ltd (PLG)
Platinum Group Metals Ltd. (Platinum Group) is a platinum focused exploration and development company conducting work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa and in Canada. The Company conducts its South African exploration and development work through its wholly owned direct subsidiary, Platinum Group Metals (RSA) (Proprietary) Limited (PTM RSA). PTM RSA holds the Company�� interests in the Project 1 platinum mine (Project 1) and Project 3. PTM RSA also holds 100% of Wesplats Holding (Proprietary) Limited (Wesplats), and a 37% interest in Wildebeest Platinum (Pty) Limited (Wildebeest), a company set up to hold prospecting rights for the exploration joint venture between the Company and Sable Platinum Mining (Pty) Ltd. (Sable) and Umnotho NREF Joint Venture. In September 2011, it purchased the Providence Copper-Nickel-Cobalt-Platinum Group Metals (Cu-Ni-Co-PGM) property from Arctic Star Exploration (Arctic Star). Advisors' Opinion:- [By Zacks Investment Research]
Investors hoping for a turnaround in precious metals prices and looking for exposure to precious metals miners could consider Platinum Group Metals (PLG), currently ranked #2 (Buy) by Zacks.
5 Best Warren Buffett Stocks For 2014: (NRTLQ)
Nortel Networks Corporation does not have significant operations. Previously, it engaged in supplying end-to-end networking products and solutions, including hardware, software, and services to service providers and enterprise customers. The company was founded in 1914 and is based in Mississauga, Canada. On January 14, 2009, Nortel Networks Corporation filed for creditor protection under the Companies' Creditors Arrangement Act in Canada.
Well, you can read more reviews here http://usemyreviews.com/buy-wideband-male-external-catheters-cheap-prices-read-reviews/.
ReplyDelete